Stingray Therapeutics

About

Stingray Therapeutics is an innate immune cancer developer with a revolutionary new cancer therapy – Vizenpistat (SR-8541A). Current immune oncology therapies are all in adaptive immunity. Our immune system functions brilliantly with two synergistic arms – innate and adaptive. Cancer turns one, the other, or both arms off. When innate immunity is off (happens in ½ of all cancers), the cancer is able to create an immune desert around the tumor which keeps the immune system from “seeing” the cancer and attacking it. Vizenpistat turns this immune desert into an immune oasis where immunity can function again to rip apart the cancer. Vizenpistat is designed to work with current adaptive immune checkpoint inhibitors to make them effective in cancers where they do not currently work, and with radiotherapies by delivering a strong secondary immune punch. 

Stingray is currently in a phase 1-2 clinical study in colorectal cancer (CRC). Vizenpistat is safe and effective, having almost completed a phase 1 study in Australia, and now starting to get the first readouts in CRC with double checkpoint inhibitor.